Latest Pharma and Biotech News
Pharmaceutical
25 March 2025 California-based clinical stage biotech Alumis today announced a collaboration and licensing agreement with Japan’s Kaken Pharmaceutical to develop, manufacture and commercialize ESK-001, a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor, for dermatology indications in Japan, with the option to expand the license to include rheumatological and gastrointestinal diseases.
Today's issue
Refine Search
Pharmaceutical
The Trump administration plans to pull US funding from Gavi, the global vaccine alliance that helps deliver immunizations to children in lower-income countries, according to internal documents obtained by the New York Times. 26 March 2025
Pharmaceutical
US biotech Exelixis has secured a sixth indication for its cancer drug Cabometyx (cabozantinib), following a green light from the Food and Drug Administration for advanced neuroendocrine tumors (NET). 26 March 2025
Pharmaceutical
The Global Trends in R&D 2025 report from contract research organization IQVIA has landed. 26 March 2025
Pharmaceutical
French independent pharma major Servier is ramping up its industrial development with the inauguration of a new production unit for the active ingredient of one of its venous medicines. 26 March 2025
Pharmaceutical
The Chinese government is contemplating a new drug reimbursement category called category C to make commercial insurance companies a major payer. If the new category is introduced, it is expected to significantly accelerate China’s innovation, said speakers at the BIOCHINA event held in Suzhou. 26 March 2025
Pharmaceutical
US pharma giant Merck & Co today announced that the European Commission (EC) has approved Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for a new indication, marking the fourth nod for the product from the regulator. 26 March 2025
Pharmaceutical
Spain-based drugmaker REIG JOFRE has signed a commercial agreement with LEO Pharma, a privately-held Danish firm specializing in medical dermatology and thrombosis. 26 March 2025
Pharmaceutical
Pharma major GSK on Tuesday said its urinary tract infection treatment gepotidacin, under the brand name Blujepa, has been approved in the USA. 26 March 2025
Biotechnology
Polygenic diseases company Character Biosciences has announced an oversubscribed $93 million Series B financing round to accelerate the advancement of its pipeline of precision therapies to treat degenerative eye diseases, starting with age-related macular degeneration (AMD). 26 March 2025
Biotechnology
The global central nervous system (CNS) market is projected grow to over $80 billion in sales in 2025 for the first time since 2013, making a significant resurgence after a decade of stagnation. 26 March 2025
Biotechnology
Theratechnologies has received approval from the US Food and Drug Administration for Egrifta WR (tesamorelin), a new formulation for injection. The treatment is indicated for the reduction of excess abdominal fat in adults with HIV who have lipodystrophy. 26 March 2025
Pharmaceutical
US biotech Cassava Sciences will shut down development of its lead Alzheimer’s disease candidate, simufilam, after the treatment failed a second late-stage trial. 26 March 2025
Biotechnology
Asgard Therapeutics, a privately-held biotech working in in vivo direct cell reprogramming for cancer immunotherapy, has named experienced immunology drug development specialist Shane Olwill its chief development officer (CDO). 26 March 2025
Pharmaceutical
The NHS Business Services Authority (NHSBSA) has released an exploratory analysis estimating that patients could have faced prescription charges totaling approximately £837 million ($1.1 billion) in the 2023/24 period without the use of prescription prepayment certificates. 26 March 2025
Pharmaceutical
Norwegian blood cancer specialist Photocure has appointed Jane Healy as vice president and general manager EMEA. 26 March 2025
Generics
Russian drug manufacturers are eliminating global players from the domestic insulin market, as their sales are steadily growing, The Pharma Letter’s local correspondent reports. 26 March 2025
Pharmaceutical
A new report by the Wall Street Journal (WSJ) reveals abuse of the 340B hospital markup program is getting worse as hospitals and middlemen find new ways to profit off the program, according to a website posting by trade group Pharmaceutical Research and Manufacturers of America (PhRMA). 26 March 2025
Pharmaceutical
California-based clinical stage biotech Alumis today announced a collaboration and licensing agreement with Japan’s Kaken Pharmaceutical to develop, manufacture and commercialize ESK-001, a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor, for dermatology indications in Japan, with the option to expand the license to include rheumatological and gastrointestinal diseases. 25 March 2025
Pharmaceutical
A newly-published randomized controlled trial (RCT) has demonstrated that Deprexis, a digital therapeutic for depression with already extensive clinical validation, shows enhanced effectiveness when used alongside transcranial infrared laser stimulation (TILS). 25 March 2025
Biotechnology
US clinical-stage biotech Syncromune today announced the appointment of Zhihong Li as chief regulatory affairs officer. 25 March 2025
All news
Pharmaceutical
The Trump administration plans to pull US funding from Gavi, the global vaccine alliance that helps deliver immunizations to children in lower-income countries, according to internal documents obtained by the New York Times. 26 March 2025
Pharmaceutical
US biotech Exelixis has secured a sixth indication for its cancer drug Cabometyx (cabozantinib), following a green light from the Food and Drug Administration for advanced neuroendocrine tumors (NET). 26 March 2025
Pharmaceutical
The Global Trends in R&D 2025 report from contract research organization IQVIA has landed. 26 March 2025
Pharmaceutical
French independent pharma major Servier is ramping up its industrial development with the inauguration of a new production unit for the active ingredient of one of its venous medicines. 26 March 2025
Pharmaceutical
The Chinese government is contemplating a new drug reimbursement category called category C to make commercial insurance companies a major payer. If the new category is introduced, it is expected to significantly accelerate China’s innovation, said speakers at the BIOCHINA event held in Suzhou. 26 March 2025
Pharmaceutical
US pharma giant Merck & Co today announced that the European Commission (EC) has approved Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for a new indication, marking the fourth nod for the product from the regulator. 26 March 2025
Pharmaceutical
Spain-based drugmaker REIG JOFRE has signed a commercial agreement with LEO Pharma, a privately-held Danish firm specializing in medical dermatology and thrombosis. 26 March 2025
Pharmaceutical
Pharma major GSK on Tuesday said its urinary tract infection treatment gepotidacin, under the brand name Blujepa, has been approved in the USA. 26 March 2025
Biotechnology
Polygenic diseases company Character Biosciences has announced an oversubscribed $93 million Series B financing round to accelerate the advancement of its pipeline of precision therapies to treat degenerative eye diseases, starting with age-related macular degeneration (AMD). 26 March 2025
Biotechnology
The global central nervous system (CNS) market is projected grow to over $80 billion in sales in 2025 for the first time since 2013, making a significant resurgence after a decade of stagnation. 26 March 2025
Biotechnology
Theratechnologies has received approval from the US Food and Drug Administration for Egrifta WR (tesamorelin), a new formulation for injection. The treatment is indicated for the reduction of excess abdominal fat in adults with HIV who have lipodystrophy. 26 March 2025
Pharmaceutical
US biotech Cassava Sciences will shut down development of its lead Alzheimer’s disease candidate, simufilam, after the treatment failed a second late-stage trial. 26 March 2025
Biotechnology
Asgard Therapeutics, a privately-held biotech working in in vivo direct cell reprogramming for cancer immunotherapy, has named experienced immunology drug development specialist Shane Olwill its chief development officer (CDO). 26 March 2025
Pharmaceutical
The NHS Business Services Authority (NHSBSA) has released an exploratory analysis estimating that patients could have faced prescription charges totaling approximately £837 million ($1.1 billion) in the 2023/24 period without the use of prescription prepayment certificates. 26 March 2025
Pharmaceutical
Norwegian blood cancer specialist Photocure has appointed Jane Healy as vice president and general manager EMEA. 26 March 2025
Generics
Russian drug manufacturers are eliminating global players from the domestic insulin market, as their sales are steadily growing, The Pharma Letter’s local correspondent reports. 26 March 2025
Pharmaceutical
A new report by the Wall Street Journal (WSJ) reveals abuse of the 340B hospital markup program is getting worse as hospitals and middlemen find new ways to profit off the program, according to a website posting by trade group Pharmaceutical Research and Manufacturers of America (PhRMA). 26 March 2025
Pharmaceutical
California-based clinical stage biotech Alumis today announced a collaboration and licensing agreement with Japan’s Kaken Pharmaceutical to develop, manufacture and commercialize ESK-001, a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor, for dermatology indications in Japan, with the option to expand the license to include rheumatological and gastrointestinal diseases. 25 March 2025
Pharmaceutical
A newly-published randomized controlled trial (RCT) has demonstrated that Deprexis, a digital therapeutic for depression with already extensive clinical validation, shows enhanced effectiveness when used alongside transcranial infrared laser stimulation (TILS). 25 March 2025
Biotechnology
US clinical-stage biotech Syncromune today announced the appointment of Zhihong Li as chief regulatory affairs officer. 25 March 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze